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Abstract
Signal transduction modulates expression and activity of cholesterol transporters. We recently demonstrated that the Ras/
mitogen-activated protein kinase (MAPK) signaling cascade regulates protein stability of Scavenger Receptor BI (SR-BI)
through Proliferator Activator Receptor (PPARa) -dependent degradation pathways. In addition, MAPK (Mek/Erk 1/2)
inhibition has been shown to influence liver X receptor (LXR) -inducible ATP Binding Cassette (ABC) transporter ABCA1
expression in macrophages. Here we investigated if Ras/MAPK signaling could alter expression and activity of ABCA1 and
ABCG1 in steroidogenic and hepatic cell lines. We demonstrate that in Chinese Hamster Ovary (CHO) cells and human
hepatic HuH7 cells, extracellular signal-regulated kinase 1/2 (Erk1/2) inhibition reduces PPARa-inducible ABCA1 protein
levels, while ectopic expression of constitutively active H-Ras, K-Ras and MAPK/Erk kinase 1 (Mek1) increases ABCA1 protein
expression, respectively. Furthermore, Mek1/2 inhibitors reduce ABCG1 protein levels in ABCG1 overexpressing CHO cells
(CHO-ABCG1) and human embryonic kidney 293 (HEK293) cells treated with LXR agonist. This correlates with Mek1/2
inhibition reducing ABCG1 cell surface expression and decreasing cholesterol efflux onto High Density Lipoproteins (HDL).
Real Time reverse transcriptase polymerase chain reaction (RT-PCR) and protein turnover studies reveal that Mek1/2
inhibitors do not target transcriptional regulation of ABCA1 and ABCG1, but promote ABCA1 and ABCG1 protein
degradation in HuH7 and CHO cells, respectively. In line with published data from mouse macrophages, blocking Mek1/2
activity upregulates ABCA1 and ABCG1 protein levels in human THP1 macrophages, indicating opposite roles for the Ras/
MAPK pathway in the regulation of ABC transporter activity in macrophages compared to steroidogenic and hepatic cell
types. In summary, this study suggests that Ras/MAPK signaling modulates PPARa- and LXR-dependent protein degradation
pathways in a cell-specific manner to regulate the expression levels of ABCA1 and ABCG1 transporters.
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Introduction
Anti-atherosclerotic properties of HDL and apolipoprotein A-I
(apoA-I) include their ability to promote reverse cholesterol
transport (RCT), the removal of excess cholesterol from peripheral
tissues to the liver for bile secretion [1–3]. HDL receptors and
ABC transporters are key molecules in cholesterol efflux from
macrophages, with ABCA1 facilitating transfer of cholesterol onto
apoA-I, while ABCG1 and SR-BI augment export of cholesterol
onto HDL. In addition, ABCA1 in the liver is required for
cholesterol export during HDL biogenesis, while hepatic SR-BI
has a prominent role for the selective uptake of cholesteryl esters
from HDL [1–3]. The molecular mechanisms of cholesterol
transfer via ABC transporters and SR-BI have been studied
extensively, however the signaling events that trigger mobilization
of cellular cholesterol pools, or alternatively, alter expression and
activity of cholesterol transporters are not fully understood. An
increasing number of studies suggest that cell surface binding and
internalization of HDL and apo-AI activate signaling proteins such
as protein kinase A and C (PKA, PKC), Rac/Rho GTPases, Janus
Kinase 2 (JAK2), calmodulin and MAPK to modulate the ability
of cells to export cholesterol [4–6].
Given their potential as pharmaceutical targets, the control of
ABC transporter and SR-BI expression received great attention,
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and transcriptional upregulation of ABCA1, ABCG1 and SR-BI
via nuclear receptors, including LXR, PPARa and PPARc, is well
established [7,8]. Yet, post-transcriptional mechanisms contribute
to modify ABC transporters and SR-BI levels. Lysosomal as well as
ubiquitin-dependent ABCA1 degradation implicated ABCA1
protein turnover as a modulator of cholesterol efflux [9–11]. In
addition, ABCA1 contains a proline-glutamic acid-serine-threo-
nine-rich (PEST) peptide sequence that accounts for calpain-
mediated degradation along the lysosomal pathway [12–14].
Similarly, hepatic SR-BI protein levels are regulated post-
transcriptionally by vitamin E, insulin, estrogen, the adaptor
protein PDZ domain-containing protein 1 (PDZK1), as well as
fibrates stimulating PPARa-dependent degradation pathways [15–
18]. Little is known about ABCG1 protein turnover, but
ubiquitination as well as calpain have recently been identified as
influencing ABCG1 protein levels in macrophages [11,19–21].
Activation of several signaling proteins, including PKC, PKA,
Rac/Rho GTPases, JAK2 and calmodulin have been shown to
affect ABCA1 and SR-BI protein stability [5–7]. Some signaling
cascades are induced by HDL or apoA-I and linked to
phosphorylation events targeting ABCA1, while others act via
nuclear receptors and/or ubiquitination and proteosomal degra-
dation pathways to modify ABCA1 and SR-BI levels [5–7,13,16].
In addition, we and others have demonstrated that Mek/Erk
kinases contribute to alter ABCA1 and SR-BI expression and
activity, most likely via nuclear receptors [22–25]. In lung
epithelial cells, enhanced Erk1/2 signaling upregulates PPARa
levels to increase ABCA1 mRNA expression and consequently,
phospholipid efflux [22]. In macrophages, Erk1/2 inhibition
protects LXR-induced ABCA1 mRNA from degradation to
promote cholesterol efflux [23]. In contrast, in HepG2 cells
Mek1/2 kinases act upstream of PPARc- and LXRb-dependent
ABCA1 protein degradation [24]. Furthermore, we showed that
inhibition of HDL-induced and SR-BI-mediated activation of the
Ras/MAPK pathway [25–27] might establish feedback loops via
PPARa to reduce SR-BI protein levels and activity in CHO cells
and hepatic HuH7 cells [28]. In line with Erk1/2 kinases
modulating nuclear receptor activity [29–31], HDL-inducible
PPARa Ser21 phosphorylation was reduced in the presence of
Mek1/2 inhibitor. Blocking Mek1/2 activity was associated with
strongly decreased SR-BI cell surface expression and activity, as
judged by reduced uptake of HDL-derived cholesteryl-esters [28].
Hence, differential regulation of ABCA1 and SR-BI protein
levels in peripheral and hepatic cells by Mek/Erk kinases seem to
involve multiple nuclear receptors. It is yet unknown if Mek1/2
inhibition can reduce ABCA1 protein levels in hepatic cells in
a PPARa-dependent manner and if the Ras/MAPK pathway
modulates protein levels of ABCG1. Here we demonstrate that
Erk1/2 inhibition reduced ABCA1 protein stability in CHO and
HuH7 hepatocarcinoma cells treated with PPARa agonists, while
overexpression of constitutively active H-Ras, K-Ras or Mek1
increased ABCA1 expression. In addition, blocking Erk1/2
activity reduced ABCG1 protein levels in the presence and
absence of LXR agonists in ABCG1 overexpressing CHO and
HEK293 cells. This correlated with Erk1/2 inhibition strongly
decreasing HDL-inducible cholesterol efflux in ABCG1 over-
expressing CHO cells. Similar to Erk1/2 inhibition promoting
SR-BI degradation in these cells [28], blocking MAPK activity
reduced ABCA1 and ABCG1 protein stability without affecting
ABC transporter mRNA expression. In contrast, Mek1/2 in-
hibitor PD98059 increased ABCA1 and ABCG1 protein levels in
THP1 macrophages. In summary, depending on the cell-type and
their repertoire of nuclear receptors, inhibition of the Ras/MAPK
pathway could have opposite effects on ABCA1 and ABCG1
expression.
Materials and Methods
Reagents and Antibodies
Nutrient Mixture Ham’s F12, DMEM, RPMI-1640, geneticin,
cycloheximide, fenofibrate (FF), Wy-14643, GW3965, T0901317,
12-O-tetradecanoylphorbol-13-acetate (TPA) were from Sigma.
[3H]-Cholesterol was from Amersham Pharmacia Biotech.
PD98059, U0126, CI-1040 were from Calbiochem. SDS-PAGE
molecular weight markers were from Fermentas. Rabbit poly-
clonal antibodies against ABCA1, ABCG1 and SR-BI were from
Novus. Rabbit polyclonal anti- PPARa was from Santa Cruz.
Mouse monoclonal anti-Pan Ras and rabbit polyclonal anti-b-
actin were from BD Transduction Laboratories. Rabbit polyclonal
antibodies against activated Mek1/2 (P-Mek1/2), Erk1/2 (P-
Erk1/2), Total Mek1/2, Total Erk1/2, glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) and Horseradish Peroxidase
(HRP) -labeled secondary antibodies were purchased from Cell
Signaling. Expression vectors encoding constitutively active H-Ras
(HRasG12V), K-Ras (GFP-KRasG12V), Mek1 (Mek215-DD) and
PPARa were kindly provided by John F. Hancock (Dallas, USA),
Brian Gabrielli (Brisbane, Australia), and Bart Staels (Lille,
France), respectively. CHO, THP1, HEK293 and HuH7 cell
lines were from the American Type Culture Collection (ATCC,
Manassas, VA, USA). CHO cells overexpressing ABCG1 (CHO-
ABCG1) [19] were kindly provided by Ingrid Gelissen (Sydney,
Australia). High Density Lipoproteins (HDL3, density 1.125–
1.21 g/ml) were isolated from the plasma of normolipidemic
volunteers by sequential ultracentrifugation in the 1.14,
d ,1.21 g/ml density range as described [28]. Purified apoA-I
was prepared as described [32].
Cell Culture
CHO wild-type (wt) and CHO overexpressing ABCG1 (CHO-
ABCG1) were grown in Ham’s F12, HEK293 in DMEM, HuH7
in DMEM and F12 (1:1), THP1 in RPMI-1640 together with 10%
fetal calf serum (FCS), L-glutamine (2 mM), penicillin (100 U/ml)
and streptomycin (100 mg/ml) at 37uC, 5% CO2. THP1
monocytes were differentiated with 2 nM TPA for 24 h before
treatment with MEK inhibitors. For overexpression of
HRasG12V, GFP-KRasG12V, Mek215-DD or PPARa, 1–
26105 cells were transfected with 1.5 mg Qiagen-purified DNA
and 6 ml of Lipofectamine 2000 (Invitrogen) as described [28].
Real Time RT-PCR
Total RNA from HEK293 cells was extracted using the Trizol
and RNeasy system (Macherey-Nagel, Germany) according to
manufacturer’s instructions. 1 mg of RNA was reverse transcribed
with the High Capacity cDNA Archive Kit (Applied Biosystems)
and Real Time RT-PCR was performed as described previously
[33]. Assay-on-Demand primer sets to amplify cDNA fragments
encoding ABCA1, ABCG1 and TATA Box Binding Protein (TBP)
sequences were from Applied Biosystems. Relative ABCA1 and
ABCG1 expression was calculated by normalization to the
housekeeper mRNA (TBP) as described [34].
Cholesterol Efflux Assays
For the determination of cholesterol efflux, 2–56105 cells (in
triplicate) were labeled overnight with [3H]-Cholesterol
(26106 cpm/ml) as described [28]. Non-internalized radioactivity
was removed by extensive washing with PBS. Then cells were
incubated in Ham’s F12/0.1% BSA650 mg/ml HDL3 (total
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protein) or 30 mg/ml apoA-I for 6 h, respectively. The media were
harvested, cells were lysed in 0.1 N NaOH and the total cellular
protein was determined [35]. The radioactivity in the media and
cell lysate was measured by scintillation counting [28]. The ratio of
released/(released and cell-associated) radioactivity6100 was
calculated and is given in (%).
Preparation of Cellular Extracts and Western Blot Analysis
Cells were harvested in lysis buffer (20 mM Tris-HCl, pH 7.5,
2 mM EDTA, 100 mM NaCl, 5 mM MgCl2, 1% (v/v) Triton X-
100, 5 mM NaF, 10% (v/v) glycerol, 0.5% (v/v) 2-mercaptoetha-
nol, 0.1 mM Na3VO4 and protease inhibitors). After centrifuga-
tion at 10000 g the protein concentration of the cleared cell lysate
was determined. Cell lysates were separated by 10–12.5% SDS-
PAGE and transferred to Immobilon-P (Millipore). Proteins were
detected using their specific primary antibodies, followed by HRP-
conjugated secondary antibodies and enhanced chemilumines-
cence detection (ECL, Amersham).
PPARa Knockdown Studies
1–26105 HuH7 cells were transfected with 1.5 mg SureSilen-
cing shRNA plasmids (SABiosciences) targeting human PPARa at
Pos. 552–572 (59-ggagcattgaacatcgaatgt-39), 954–974 (59-atgggtt-
tataactcgtgaat-39), and 1273–1293 (59-tcaggaaaggccagtaacaat-39)
and Lipofectamine 2000 as described [28]. Studies were con-
ducted after 72 h. Scrambled shRNA served as negative control
(59-ggaatctcattcgatgcatac-39).
Subcellular Fractionations
For the isolation of plasma membrane-enriched fractions,
lysates from 16107 CHO-ABCG1 cells were separated on Percoll
gradients as described [26,28]. Cells were washed twice in 0.25 M
Sucrose, 1 mM EDTA, 20 mM Tris-HCl, pH 7.8 plus protease
inhibitors, collected and centrifuged. The postnuclear supernatant
(PNS) was layered on top of 10 ml of 30% Percoll and centrifuged
at 84.000 g for 30 min in a Beckman 70.1 TI rotor. The plasma
membrane fraction in the middle of the gradient was isolated
(1 ml), concentrated and analyzed for the amount of ABCG1 and
Ras.
Results
Ras/MAPK Signaling Regulates ABCA1 Expression in CHO
and HuH7 Cells
Recent studies identified cell-type specific and differential
involvement of Mek/Erk kinases in post-transcriptional pathways
involving PPARc and LXRa/b that regulate ABCA1 protein
levels [23,24]. In addition, we showed that Mek1/2 inhibition
reduced PPARa-dependent SR-BI protein stability in CHO,
HEK293 and hepatic HuH7 cells, but not peripheral cells, such as
bovine aortic endothelial (BAEC) and monocytic (THP1) cell lines
[28]. To determine if the Ras/MAPK pathway could alter
ABCA1 protein levels, possibly in a PPARa-dependent manner,
we first examined CHOwt cells, which have been proven
a valuable model to study the involvement of ABCA1 in
cholesterol transport [36,37], exhibit HDL-inducible Ras/MAPK
activity, Ras/MAPK-inducible PPARa phosphorylation and SR-
BI expression [25–28]. CHOwt cells express low, but detectable
levels of ABCA1 [36], as confirmed by western blot analysis using
antibodies raised against human ABCA1 (see lane 1 in Fig. 1A and
1B). Similar to our previous studies, both moderate and high
PPARa overexpression in CHOwt cells only modestly increased
basal levels of its target genes in the absence of PPARa agonists,
including SR-BI [28] and as shown here, ABCA1 (Fig. 1A,
compare lane 1 with lane 2 and 3). Consistent with previous
findings [7,8], PPARa overexpression strongly stimulated ABCA1
expression in FF-treated CHOwt (Fig. 1A, lane 4). Wy-14643
(PPARa agonist) increased ABCA1 expression 3.861.4 fold in
CHOwt cells (Fig. 1A, compare lane 5 and 7), and similar results
were obtained in FF-treated CHOwt cells (not shown). Incubation
with the Mek1/2 inhibitor PD98059 [38] reduced basal ABCA1
levels (compare lane 5 and 6) as well as Wy-14643 -induced
ABCA1 levels by 89.464% (*, p = 0.039; Fig. 1A, compare lane 7
and 8). In contrast, ectopic expression of constitutively active
HRas (HRasG12V), KRas (KRasG12V) and Mek1 (Mek215-DD)
mutants in CHOwt cells increased ABCA1 protein levels 3.9 and
4.1 -fold, respectively (**, p = 0.0039; Fig. 1B). As HDL-induced
Ras/MAPK signaling stimulates PPARa Ser21 phosphorylation in
CHO cells [28], one can speculate that the Ras/MAPK pathway
triggers phosphorylation events targeting PPARa that contribute
to regulate ABCA1 expression in these cells.
ABCA1 is important for hepatic HDL biogenesis, and we next
investigated if similar mechanisms exist in hepatic HuH7 cells
(Fig. 2A). Indeed, Mek1/2 inhibition in these cells reduced
ABCA1 levels in the absence of Wy-14643 by 35.969.4% (*,
p = 0.002; Fig. 2A, compare lane 1 and 2). Treatment of HuH7
cells with PPARa agonist induced ABCA1 expression 1.760.3 -
fold (**, p = 0.0027; compare lane 1 and 3), which was drastically
reduced by 77.968.1% in the presence of PD98059 (**,
p = 0.0031; compare lane 3 and 4). The second generation
Mek1/2 inhibitor CI-1040 (PD184352) [39] also reduced ABCA1
expression in Wy-14643 stimulated HuH7 cells (compare lane 5–
7).
To substantiate the involvement of PPARa and Mek1/2 in
ABCA1 expression, HuH7 cells were transfected with siRNA to
knockdown endogenous PPARa (Fig. 2B). As shown above, Wy-
14643 treatment of HuH7 cells transfected with control siRNA
induced ABCA1 protein levels (Fig. 2B, compare lane 1 and 2).
PPARa knockdown ($95%) correlated with strongly reduced
ABCA1 levels in Wy-14643 incubated cells (compare lane 3 and
4). Similar to Fig. 2A, PD98059 strongly abrogated ABCA1
expression in Wy-14643 stimulated cells (compare lane 5 and 6).
In PPARa–depleted and Wy-14643-treated HuH7 cells, ABCA1
expression was strongly downregulated in the presence or
absence of Mek1/2 inhibitor (lane 7–8). ABCA1 downregulation
was less severe in PPARa-depleted cells in the presence of
PD98059 (compare lane 7 and 8). This could be due to
incomplete PPARa knockdown/inhibition or indicate that
Mek1/2 inhibition in HuH7 hepatocytes modulates ABCA1
expression probably not exclusively via PPARa, but also via
other nuclear factors, possibly PPARc and LXRb, as shown for
HepG2 cells [24].
In contrast to the results obtained from CHO and HuH7 cells
(see above), Mek1/2 inhibition increases ABCA1 expression in
RAW and mouse peritoneal macrophages in a dose-dependent
manner [23]. Mek1/2 activation in macrophages can occur
through various signaling pathways. HDL-induced activation of
Mek/Erk kinases has been demonstrated in various cell types [25–
28,40–42] and Mek/Erk phosphorylation upon HDL incubation
in TPA-differentiated THP1 monocytes indicates that this
signaling cascade also exists in human macrophages (Fig. 2C,
compare lane 1 and 2). HDL-induced Mek/Erk phosphorylation
in THP1 macrophages is effectively inhibited by PD98059
(compare lane 2 and 3). To determine if Mek/Erk inhibition
could also elevate ABCA1 expression in a human macrophage
model system, THP1 monocytes were differentiated with TPA for
24 h before treatment 610 mM PD98059 (Fig. 2D). Mek1/2
inhibition increased ABCA1 protein expression approximately 2-
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fold in these cells (*, p = 0.032; compare lane 1 and 2), which is
comparable to data using similar PD98059 concentrations in
RAW macrophages [23]. Consistent with our previous data [28],
PD98059-incubated THP1 macrophages also showed a small, but
not significant increase of SR-BI expression compared to controls
(Fig. 2D). It remains to be determined if HDL-induced Erk1/2
activation contributes to modulate cholesterol efflux via controlling
ABCA1 levels in macrophages in vivo, however findings from the
hepatic HuH7 cells and THP1 macrophage model support
opposite and cell-specific roles for Mek/Erk kinases in the
regulation of ABCA1 expression.
Mek1/2 Inhibition Reduces ABCG1 Expression in CHO
Cells
Based on the Ras/MAPK pathway modulating SR-BI [28] and
ABCA1 (Fig. 1–2) expression, we speculated that Mek1/2
inhibition could also modify the protein levels of ABCG1, another
ABC transporter implicated in HDL cholesterol transport. Given
LXR-inducible ABCG1 expression [1–3,9], Mek kinases acting
upstream of LXR in HepG2 cells [24], and the very low amounts
of endogenous ABCG1 in CHOwt cells [43], we first utilized
CHO cells stably overexpressing ABCG1 (CHO-ABCG1) [43]
treated 6 LXR agonist (GW3965) to determine if Mek1/2
inhibition could reduce ABCG1 levels. Indeed, PD98059 reduced
ABCG1 protein levels by 33610 and 5265% (*, p= 0.022 and
0.035; Fig. 3A, compare lane 1 and 2, 3 and 4) in CHO-ABCG1
cells incubated 6 GW3965, respectively. Endogenous ABCG1
levels in HEK293 cells, a common model to study cholesterol
transport, ABCA1-dependent signaling and nuclear receptor
activity [4,28,31], treated 6 GW3965 were also reduced by
approximately 40–70% with PD98059 (*, p = 0.040, 0.035 and
0.026; Fig. 3B, compare lane 1 and 2, 3 and 4). Using
a commercial rabbit polyclonal ABCG1 antibody in this western
blot analysis, we also observed an additional GW3685-inducible
and PD98059-sensitive protein (see arrowhead, lane 3). These
findings may indicate limitations of the human HEK293 model for
ABCG1 expression studies when using rabbit polyclonal ABCG1
antibodies. Although we cannot completely rule out an unspecific
signal not related to ABCG1, this might possibly indicate post-
translational modification or expression of another ABCG1
isoform [19]. Further supporting an opposite role for Mek/Erk
kinases in ABC transporter expression in macrophages, ABCG1
levels increased 1.4–1.6–fold in PD98059-incubated THP1
macrophages (*, p = 0.041; Fig. 3C, compare lane 1, 3 and 4).
Co-incubation of LXR agonist and PD98059 did not further
increase ABCG1 levels (not shown). Taken together, MAPK
inhibition reduces ABCA1 (Fig. 1A, 2A–B), ABCG1 (Fig. 3A–B)
and SR-BI [28] levels in CHO, HuH7 and HEK293 cells. In
contrast, Mek1/2 inhibitor PD98059 increases ABCA1 (Fig. 2D),
ABCG1 (Fig. 3D) expression and modestly elevated SR-BI protein
levels (Fig. 2D) in THP1 macrophages.
Blocking Mek1/2 Activity Reduces ABCG1-mediated
Cholesterol Efflux in CHO Cells
Erk1/2 inhibition has been shown to affect both ABCA1
expression and activity [22,23], so we next aimed to identify if
reduced ABCG1 levels in PD98059-treated CHO-ABCG1 cells
would correlate with diminished ABCG1 transporter activity. We
first determined ABCG1 cell surface expression. Western blot
analysis of Ras-containing plasma membrane fractions isolated
from Percoll gradients identified decreased ABCG1 levels in
CHO-ABCG1 cells treated with PD98059 (*, p= 0.028; Fig. 4A).
Next we examined the ability of PD98059 to inhibit HDL-
inducible Ras/MAPK activation and cholesterol efflux in ABCG1
overexpressing CHO cells. As shown for CHOwt and CHO cells
overexpressing SR-BI [28], HDL strongly activates Mek1/2 and
Erk1/2 kinases (P-Mek1/2, P-Erk1/2) in CHO-ABCG1 cells
(Fig. 4B, compare lane 1 and 2). HDL-induced Mek1/2 and
Erk1/2 phosphorylation (compare lane 2 and 3) in these cells was
inhibited with PD98059, while phosphorylation of other Ras
Figure 1. Ras/MAPK signaling regulates ABCA1 expression. (A+B) CHOwt cells were transfected with empty vector (2), PPARa (+),
constitutively active H-Ras (HRasG12V), K-Ras (GFP-KRasG12V) or Mek1 (Mek215-DD) as indicated. (A) After 24 h cells were treated620 mM
Fenofibrate (FF), 20 mM Wy-14643 and610 mM PD98059 as indicated. Cell lysates were analyzed for ABCA1, PPARa, activated Mek/Erk1/2 (P-Mek1/2,
P-Erk1/2), Total Mek1/2 and Erk1/2, Ras and b-actin. Molecular weight markers are shown. ABCA1 levels were quantified, normalized to actin and
represent the mean 6 S.D. from 3 independent experiments. * and **, p,0.05 and p,0.01 for Student’s t-test, respectively.
doi:10.1371/journal.pone.0062667.g001
MAPK Erk1/2 Regulates ABCA1 and ABCG1 Expression
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e62667
effectors, such as Akt, was not altered (not shown). We then
analyzed HDL-inducible cholesterol efflux in CHO-ABCG1 cells
6 PD98059 (Fig. 4C). CHO-ABCG1 cells were labeled for 24
hours with [3H]-Cholesterol, pre-incubated for 4 h610 mM
PD98059, followed by an incubation with 50 mg/ml HDL or
30 mg/ml apoA-I for 6 h. Cells and media were assayed for
radioactivity and efflux was determined as the percentage of total
cholesterol in the culture. As shown previously [28], PD98059
alone did not affect [3H]-cholesterol internalization, cell viability
or basal cholesterol efflux, nor did apoA-I activate the Ras/MAPK
pathway in CHOwt cells [26] (not shown). Furthermore,
treatment with PD98059 alone, and consistent with previous
studies in CHO cells [43], incubation with apoA-I (30 mg/ml) 6
PD98059 did not alter basal cholesterol efflux activities. In
contrast, HDL effectively stimulated cholesterol efflux in CHO-
ABCG1 cells (**, p = 0.0017; 5.660.7–fold). Yet, efflux of [3H]-
cholesterol-loaded CHO-ABCG1 cells onto HDL in the presence
of PD98059 was reduced by 53611% (*, p = 0.012). Hence, the
Ras/MAPK activity modulates ABCG1 expression and activity in
CHO-ABCG1 cells.
Ras/MAPK Signaling Modulates ABCA1 and ABCG1
Protein Stability
In CHO, HEK293 and HuH7 cells, Mek1/2 inhibition
enhanced SR-BI protein degradation while SR-BI mRNA levels
remained unchanged [28]. To identify if Ras/MAPK signaling
modifies ABCA1 and ABCG1 mRNA or protein expression, we
first measured ABCA1 and ABCG1 mRNA 6 U0126, another
specific Mek1/2 inhibitor [44], by Real Time RT-PCR in
HEK293 cells (Fig. 5A). While Mek inhibition reduced ABCA1
and ABCG1 protein levels in unstimulated cells (Fig. 2A, 3A–B),
mRNA levels of unstimulated HEK2936U0126 remained un-
changed. As expected, treatment with LXR agonist (1 mM
T0901317) increased ABCA1 and ABCG1 mRNA levels approx-
imately 5 and 6–fold, respectively. However, co-incubation with
U0126 did not significantly reduce ABCA1 or ABCG1 mRNA
expression (Fig. 5A;+T0901317, compare white and black
columns). Similarly, mRNA levels of ABCA1, ABCG1 and SR-
BI remained unchanged upon Mek1/2 inhibition in primary
mouse hepatocytes treated with the second generation Mek1/2
inhibitor CI-1040 [39] (not shown).
Figure 2. Mek1/2 inhibition reduces ABCA1 expression in HuH7 hepatocytes. (A) HuH7 cells were incubated for 24 h 620 mM Wy-14643
with or without 10 mM PD98059 or CI-1040 as indicated. Cell lysates were analyzed by Western blotting for expression levels of ABCA1. ABCA1 levels
in each lysate were quantified and normalized to the amount of b-actin. The mean values 6 S.D. of 3 independent experiments are given. *and **,
p,0.05 and p,0.01 for Student’s t-test, respectively. (B) HuH7 hepatocytes were transfected with control RNAi (2) or RNAi targeting PPARa (see
Material and Methods). 72 h after transfection, cells were treated for an additional 24 h 620 mM Wy-14643 and 10 mM PD98059 as indicated.
Expression of ABCA1, PPARa, and b-actin was analyzed. Blots are representative for 2 independent experiments. (C) THP1 monocytes were
differentiated with 2 nM TPA for 24 h, pre-incubated for 60 min 610 mM PD98059 (PD), stimulated 6 HDL3 (50 mg/ml) for 3 min and lysates were
analyzed for activated Mek1/2 (P-Mek1/2), Erk1/2 (P-Erk1/2), Total Mek1/2 and Total Erk1/2. Blots are representative for 3 independent experiments.
(D) TPA-differentiated THP1 monocytes were incubated 610 mM PD98059 (PD) for 24 h as indicated. Western blot analysis of ABCA1, SR-BI and b-
actin was quantified. *p,0.05 for Student’s t-test. Molecular weight markers are shown.
doi:10.1371/journal.pone.0062667.g002
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Finally we compared ABCA1 and ABCG1 protein stability,
which both have a short half-life and are rapidly degraded [10,19],
in HuH7, CHO-ABCG1 and THP1 cells, respectively (Fig. 5B–
D). To examine ABCA1 protein turnover, HuH7 cells were
incubated with 20 ng/ml cycloheximide to inhibit protein
synthesis for 0–4 h 6 Mek1/2 inhibitor PD98059 (Fig. 5B).
ABCA1 levels remained constant over 2 h and were strongly
reduced after 4 h in controls (compare lane 1–3, see white columns
for quantification). In contrast, accelerated ABCA1 protein
degradation in the presence of PD98059 was evident already
after 2 h, with ABCA1 protein levels being reduced by 45.668.6%
(*, p = 0.010 and 0.038; lane 4–6, see black columns for
quantification).
Primary hepatocytes and hepatic HuH7 cells express very little
ABCG1, making it difficult to quantify ABCG1 protein degrada-
tion in these cells by western blotting. Therefore, to examine
ABCG1 turnover, ABCG1 overexpressing CHO-ABCG1 cells
were treated with cycloheximide 6 Mek1/2 inhibitor PD98059
and ABCG1 levels were monitored for 0–8 h (Fig. 5C). After 4 and
8 h, ABCG1 protein levels in cycloheximide-treated CHO-
ABCG1 cells were reduced by 35.167.3 and 33.5613.3%,
respectively (compare lane 1–4, white columns for quantification).
In the presence of PD98059, ABCG1 degradation was more
pronounced after 8 h (54.465.0%, black columns).
In line with Mek1/2 inhibition increasing ABCA1 and ABCG1
protein levels in THP1 cells (Fig. 2D, 3C), addition of Mek1/2
inhibitors to cycloheximide-treated THP1 cells slightly increased
ABCA1 and ABCG1 protein stability by 1.4–2.0 -fold after 4–8 h,
respectively (Fig. 5D, compare lanes 1–3 with 4–6). These findings
possibly suggest opposite effects of Erk1/2 inhibition on degrada-
tion pathways that regulate ABCA1 and ABCG1 protein levels in
HuH7 and CHO cells (Fig. 5B–C) compared to THP1 cells. Erk1/
2 inhibition protecting ABCA1 mRNA degradation in macro-
phages, as shown by others [23], could further add to increase
ABC transporter expression in PD98059-incubated THP1 cells.
Taken together, Mek/Erk kinase inhibition is a common module
to reduce not only SR-BI [28], but also ABCA1 and ABCG1
protein stability in HuH7 and CHO cells.
Discussion
In this study we demonstrate that Ras/MAPK inhibition
reduced protein levels of ABCA1 and ABCG1 in CHO,
HEK293 and HuH7 cells, possibly via nuclear receptor (PPARa,
LXR) -inducible degradation pathways. In these cells, Ras/MAPK
signaling modulates ABCA1 and ABCG1 cell surface expression
and activity. In contrast, blocking Mek1/2 activity increased
ABCA1 and ABCG1 expression in THP1 macrophages. Thus,
cell-specific regulation of ABCA1 and ABCG1 protein stability
and cell surface expression via the Ras/MAPK signaling cascade
could contribute to fine-tune reverse cholesterol transport.
The signal transduction pathways that participate in the
regulation of ABC transporters are complex and poorly un-
derstood [4–6]. Several kinases, including PKC and PKA, directly
phosphorylate ABC transporters. PKCa phosphorylates threonine
residues T1286 and T1305 within the C-terminal PEST motif of
ABCA1 to regulate calpain-dependent ABCA1 degradation
[14,45]. Another PKC family member, PKCd, destabilizes
ABCA1 via increased ABCA1 serine phosphorylation [46]. In
addition, PKA-mediated phosphorylation of serine residues S2054
and S1042 stimulates ABCA1-mediated cholesterol efflux onto
apoA-I [47,48]. Besides PKC and PKA, protein kinase CK2 has
also been implicated to phosphorylate and modulate ABCA1
activity [49]. With respect to ABCG1, recent studies identified
serine, threonine and tyrosine phosphorylation of ABCG1 [20], as
Figure 3. Ras/MAPK inhibition reduces ABCG1 expression in CHO cells. (A–C) CHO-ABCG1 (A), HEK293 (B) and THP1 macrophages (C) cells
were incubated 650 mM GW3965 and 10 mM PD98059 for 24 h as indicated. Cell lysates were analyzed for ABCG1, activated Erk1/2 (P-Erk1/2), Total
Erk1/2 and b-actin. ABCG1 levels (see arrow) were quantified and normalized to b-actin. The arrowhead points at an additional GW3685-inducible and
PD98059-sensitive protein (lane 3). Representative western blots for 3 independent experiments per cell line are shown. Molecular weight markers
are shown. *, p,0.05 for Student’s t test.
doi:10.1371/journal.pone.0062667.g003
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well as p38MAPK and JNK2-dependent pathways to promote
ABCG1 serine phosphorylation and degradation [50].
To date, Mek and Erk kinases have not been identified to
directly phosphorylate ABCA1 and ABCG1. As described above,
Mek/Erk kinases rather seem to regulate ABCA1 and ABCG1
expression via nuclear receptors [22–24,28]. Mek/Erk kinases can
control nuclear receptors through multifaceted pathways including
transcriptional and post-transcriptional regulation of PPARa/c
and LXR [22,23,29,51], PPAR/LXR target gene mRNA stability
[23] and PPARa/c ligand production [52], as well as nuclear
translocation of PPARs [53]. Recruitment of PPAR/LXR co-
activators/repressors also has to be considered as Erk1/2
modulates co-repressor nuclear receptor co-repressor 1 (NCoR)
activity [54] and phosphorylates retinoic acid receptors (RXRs),
which impairs co-activator recruitment [55].
We previously demonstrated that enhanced Ras/MAPK
signaling in CHO and HEK293 cells did not alter PPARa
expression or localization, but increased Ser21-PPARa phosphor-
ylation [28]. Erk1/2 phosphorylation events targeting PPARs are
well documented [29,30] and both PPARa and PPARc contain
MAPK phosphorylation sites that modulate their transcriptional
activity. Erk1/2-mediated transactivation of PPARa occurs at
serine residues S12 and S21 and PD98059 treatment blocks
PPARa activity [29,30]. In contrast, Erk2-mediated phosphory-
lation of S82 inhibits PPARc1 transcriptional activity [29,30].
These findings were predominantly derived from studies related to
insulin signaling, but we showed that PD98059 interferes with
HDL–induced S21-PPARa phosphorylation [28], indicating
similar events during HDL-mediated signal transduction and
RCT. Also, HDL-induced and MAPK-mediated phosphorylation
of PPARc in RAW macrophages is associated with reduced
expression of PPARc-responsive genes [53]. Most relevant to
RCT, Erk1/2 inhibition correlated with decreased PPARc
phosphorylation in vivo, which was associated with increased
PPARc activity, elevated ABCA1 expression and reduced size of
atherosclerotic lesions [56].
It remains to be determined how Mek1/2 inhibition alters
ABCG1 protein expression in the presence of LXR agonists. In
macrophages, Erk1/2 inhibition synergizes with LXR activation
to induce ABCA1 expression [23]. Alternatively, in HepG2 cells it
was proposed that Mek1/2 inhibition might interfere with direct
interaction of LXRb with ABCA1 [24]. Similar mechanisms
might exist in the CHO and HEK293 models analyzed in this
study. However, although LXRa becomes phosphorylated at
a MAPK consensus site at S198, the physiological relevance of this
phosphorylation is still unclear [31].
We previously showed that Mek1/2 inhibition promotes
proteasomal degradation of SR-BI [28]. Interestingly, ubiquitin-
Figure 4. Ras/MAPK signaling modulates ABCG1 activity in CHO-ABCG1 cells. (A) CHO-ABCG1 cells were incubated 610 mM PD98059 for
24 h as indicated and subjected to subcellular fractionation through Percoll gradients. Ras-containing plasma membrane fractions (PM) in the middle
of the gradient were isolated and analyzed for the amount of ABCG1, and markers for cytosol (GAPDH) and plasma membrane (Ras). For comparison,
western blot analysis of ABCG1, GAPDH (cytosol) and Ras from whole cell lysates (WCL) is shown. (B) CHO-ABCG1 cells were starved, pre-incubated for
60 min 610 mM PD98059 (PD) and stimulated 6 HDL3 (50 mg/ml) for 3 min at 37uC as indicated. Western blot analysis of activated Mek1/2 (P-Mek1/
2), Erk1/2 (P-Erk1/2), Total Mek1/2 and Erk1/2 from each lysate is shown. (C) CHO-ABCG1 cells were incubated with [3H]-Cholesterol (26106 cpm/ml)
for 24 h, washed with PBS, and incubated with HDL3 (50 mg/ml) or apoA-I (30 mg/ml) for 6 h610 mM PD98059. The ratio of released and cell-
associated radioactivity was determined, normalized to total cell protein and the amount of efflux is given in (%). The background efflux obtained
from CHOwt was equivalent to 1.5–3.06105 cpm/mg cell protein. *and **, p,0.05 and p,0.01 for Student’s t test.
doi:10.1371/journal.pone.0062667.g004
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dependent ABCA1 and ABCG1 degradation has also been
observed [10,11]. This degradation pathway is commonly initiated
by serine/threonine phosphorylation or dephosphorylation events
to recruit ubiquitin ligases, followed by ubiquitination of the target
protein. Depending on the cell type, the same phosphorylation/
dephosphorylation event can activate or inhibit the ubiquitin-
proteasome machinery [57], hence providing opportunities for
Mek/Erk kinases to prevent or enhance ABCA1, ABCG1 and SR-
BI protein turnover in a cell-specific manner. Along these lines,
comparison of gene arrays from livers of fibrate-treated wildtype
and PPARa ko-mice and monkeys identified ,30 upregulated
PPARa target genes encoding for proteasome subunits and
ubiquitin-activating/conjugating enzymes [58–60]. Also, the E2-
conjugating enzyme Ubc9 and Sumo E3 ligase PIASc promote
recruitment of co-repressor NCoR to PPARa in HuH7 cells [61].
Hence, nuclear receptor-dependent pathways seem to affect
multiple proteins involved in the machinery that controls the
protein turnover of ABC transporters.
The diverse action of phosphorylation events and nuclear
receptors on the multifactorial proteasome machinery adds to the
complexity of the physiological relevance of signal transduction
targeting ABC transporters and HDL receptors in RCT. Since the
key findings of our study were derived from various cell culture
models, future in vivo studies using mouse models will have to
substantiate a role for the Ras/MAPK pathway in modulating
protein stability of ABC transporters, HDL metabolism and RCT.
We speculate that HDL-induced activation of Ras/MAPK could
be an opportunity to fine-tune the activity and contribution of
Figure 5. Mek1/2 inhibition reduces ABCA1 and ABCG1 protein stability. (A) 1 mg of RNA extracted from HEK293 cells treated 6 LXR
agonist (1 mM T0901317) and Mek1/2 inhibitor (10 mM U0126) was reverse transcribed and Real Time RT-PCR to amplify ABCA1, ABCG1, and TATA
Box Binding Protein (TBP) cDNA fragments was performed as described [28]. Relative expression from 2 independent experiments with duplicate
samples is given and was calculated by normalization to the housekeeper mRNA (TBP). (B–D) HuH7 (B) and CHO-ABCG1 (C) treated with 20 mM Wy-
14643 or 50 mM GW53965 overnight and PMA-differentiated THP1 monocytes (D) were incubated with 20 ng/ml cycloheximide (CHX)610 mM
PD98059 (PD) for 0–4 (B) and 0–8 h (C, D) as indicated. Western blot analysis of ABCA1, ABCG1 and b-actin in each lysate of a representative
experiment is shown. The mean values 6 S.D. of ABCA1 and ABCG1 expression levels (n = 2) are given. *, p,0.05 for Student’s t test.
doi:10.1371/journal.pone.0062667.g005
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PPARa, PPARc and LXR in peripheral and hepatic ABC
transporters and SR-BI expression. Identifying the physiological
stimuli that enable Mek/Erk kinases to differentially regulate the
protein stability of ABC transporters and SR-BI may provide
insights into the contribution of growth factors, insulin and
hormones for hepatic ABCA1 and SR-BI activity and deliver clues
to explain how Ras/MAPK overactivation contributes to athero-
sclerotic lesion development [62–64].
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